Thai Huu Ho

List of Publications by Citations

70 papers	5,716 citations	30 h-index	75 g-index
79 ext. papers	7,331 ext. citations	9 avg, IF	4.86 L-index

#	Paper	IF	Citations
70	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell*, **2017**, 171, 540-556.e25	36.2	961
69	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *New England Journal of Medicine*, **2016**, 374, 135-45	59.2	753
68	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science*, **2018**, 359, 801-806	33.3	562
67	Muscleblind proteins regulate alternative splicing. *EMBO Journal*, **2004**, 23, 3103-12	13	369
66	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Reports*, **2018**, 23, 313-326.e5	10.6	295
65	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. *Cell Reports*, **2016**, 14, 2476-89	10.6	228
64	Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. *Human Molecular Genetics*, **2005**, 14, 1539-47	5.6	202
63	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. *Clinical Cancer Research*, **2015**, 21, 1071-7	12.9	173
62	Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. *Journal of Cell Science*, **2005**, 118, 2923-33	5.3	157
61	The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. *Science*, **2016**, 352, 1344-8	33.3	151
60	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2016**, 22, 2445-2452	12.9	150
59	Dual Chromatin and Cytoskeletal Remodeling by SETD2. *Cell*, **2016**, 166, 950-962	56.2	128
58	Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. *Genome Research*, **2014**, 24, 241-50	9.7	124
57	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. *Cancer Immunology Research*, **2015**, 3, 1303-7	12.5	106
56	The mechanism of inhibition of Ran-dependent nuclear transport by cellular ATP depletion. *Journal of Cell Biology*, **2002**, 157, 963-74	7.3	105
55	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. *Cancer*, **2014**, 120, 1059-67	6.4	100
54	Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. *Journal of Urology*, **2016**, 195, 180-7	2.5	85

53	Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells. *Genome Biology*, **2014**, 15, R81	18.3	72
52	Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia. *ELife*, **2017**, 6,	8.9	68
51	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. *Clinical Cancer Research*, **2018**, 24, 5250-5260	12.9	65
50	Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. *Journal of Clinical Oncology*, **2018**, JCO2018792549	2.2	52
49	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. *Modern Pathology*, **2016**, 29, 34-42	9.8	40
48	Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. *European Urology*, **2017**, 71, 979-985	10.2	37
47	Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines. *Oncotarget*, **2015**, 6, 18418-28	3.3	37
46	Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. *Oncotarget*, **2016**, 7, 1927-46	3.3	36
45	Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. *Clinical Genitourinary Cancer*, **2017**, 15, e969-e975	3.3	35
44	Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 23.e9-23.e14	2.8	31
43	Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. *Cancer Immunology Research*, **2013**, 1, 378-85	12.5	31
42	DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. *Clinical Cancer Research*, **2016**, 22, 6236-6246	12.9	30
41	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. *European Urology Focus*, **2016**, 2, 204-209	5.1	30
40	Axitinib in the treatment of metastatic renal cell carcinoma. *Future Oncology*, **2011**, 7, 1247-53	3.6	27
39	Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. *Cancer Research*, **2015**, 75, 316-29	10.1	26
38	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 820-4	7.3	26
37	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. *Nature Communications*, **2021**, 12, 808	17.4	26
36	Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. *Journal of Clinical Oncology*, **2017**, 35, 3706-3713	2.2	25

35	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. *Scientific Reports*, **2016**, 6, 25	4.9	20
34	Genetic kidney cancer syndromes. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 1347-55	7.3	19
33	Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. *Cardio-Oncology*, **2017**, 3,	2.8	16
32	Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. *Journal of Proteome Research*, **2019**, 18, 331-340	5.6	16
31	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. *BMC Urology*, **2017**, 17, 19	2.2	15
30	Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, α1-4 Branching, α1-6 Branching, and α2-6 Sialylation in Cancer. *Journal of Proteome Research*, **2018**, 17, 543-558	5.6	14
29	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. *Scientific Reports*, **2020**, 10, 701	4.9	13
28	The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. *BMC Cancer*, **2015**, 15, 304	4.8	13
27	Behavior of blood plasma glycan features in bladder cancer. *PLoS ONE*, **2018**, 13, e0201208	3.7	12
26	The Impact of Pazopanib on the Cardiovascular System. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2018**, 23, 387-398	2.6	12
25	Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. *Clinical Cancer Research*, **2020**, 26, 4970-4982	12.9	11
24	Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 68.e17-23	2.8	10
23	Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis. *Journal of Translational Medicine*, **2016**, 14, 198	8.5	10
22	Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. *Cancer Medicine*, **2020**, 9, 1152-1160	4.8	9
21	A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. *PLoS ONE*, **2015**, 10, e0132831	3.7	8
20	A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. *Clinical Genitourinary Cancer*, **2017**, 15, 196-202.e1	3.3	6
19	Simple mimetics of a nuclear localization signal (NLS). *Organic Letters*, **2003**, 5, 2437-40	6.2	6
18	Molecular Inhibitor of QSOX1 Suppresses Tumor Growth. *Molecular Cancer Therapeutics*, **2020**, 19, 112-122	6.1	6

17	Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors. *Journal of Clinical Ultrasound*, **2016**, 44, 221-30	1	4
16	Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death. *European Urology Focus*, **2016**, 2, 608-615	5.1	4
15	In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma. *Cancer Medicine*, **2019**, 8, 5760-5768	4.8	3
14	Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer. *Clinical Epigenetics*, **2021**, 13, 12	7.7	3
13	Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model. *Clinical and Experimental Hypertension*, **2018**, 40, 524-533	2.2	3
12	Lgr5-positive endothelial progenitor cells occupy a tumor and injury prone niche in the kidney vasa recta. *Stem Cell Research*, **2020**, 46, 101849	1.6	2
11	ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	2
10	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. *Clinical Genitourinary Cancer*, **2017**, 15, e727-e734	3.3	1
9	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. *BMC Urology*, **2020**, 20, 173	2.2	1
8	Evolving Natural History of Metastatic Prostate Cancer. *Cureus*, **2020**, 12, e11484	1.2	1
7	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). *Oncologist*, **2021**, 26, 560-e1103	5.7	1
6	Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**,	6.2	1
5	Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 133.e9-133.e16	2.8	0
4	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.. *Nature Communications*, **2022**, 13, 1797	17.4	0
3	Phase Ib Study of Atezolizumab Plus Interferon- with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.. *Current Oncology*, **2021**, 28, 5466-5479	2.8	0
2	Sporadic RCC: Abnormalities in Histone-Modifying Genes **2015**, 153-165		
1	MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets. *International Journal of Molecular Sciences*, **2022**, 23, 5604	6.3	